Further, the consensus of Chinese experts on genetic testing for patients with PCa recommends testing for BRCA2 and BRCA1 germline mutations in patients with high-risk, locally progressive, and metastatic PCa (8). This evidence concerns the gene BRCA2 and posterior cortical atrophy.